| Literature DB >> 31142326 |
Qin Wu1,2, Lingyun Zhou1,2, Duoduo Lv1,2, Xia Zhu1,2, Hong Tang3,4.
Abstract
The tumor microenvironment (TME) is an essential intrinsic portion of hepatocellular carcinoma (HCC) for the regulation of its origination, development, invasion, and metastasis. As emerging components of the tumor-host interaction, exosomes are increasingly recognized as professional carriers of information in TME and as pivotal molecular entities involved in tumorigenic microenvironment setup. However, much remains unknown about the role of the exosome communication system within TME in the development and progression of HCC. In this review, we focus on the roles and probable mechanisms of TME in HCC and show the exosome-based immune regulation in TME to promote HCC. Multiple processes are involved in HCC, including tumor survival, growth, angiogenesis, invasion, and metastasis. We also discuss the specific roles of exosomes in HCC processes by molding hospitable TME for HCC, such as providing energy, transmitting protumor signals, and evading inhibitory signals. In addition, exosomes induce angiogenesis by changing the biological characteristics of endothelial cells and directly regulating proangiogenic and propermeability factors. Furthermore, exosomes may lead to HCC metastatic invasion by epithelial-mesenchymal transformation, extracellular matrix degradation, and vascular leakage. Finally, we summarize the therapeutic usage of exosomes in the HCC microenvironment and attempt to provide a theoretical reference for modern antitumor agents designed to target these mechanisms.Entities:
Keywords: Exosomes; Hepatocellular carcinoma; Immune regulation; Therapy; Tumor microenvironment
Mesh:
Year: 2019 PMID: 31142326 PMCID: PMC6542024 DOI: 10.1186/s13045-019-0739-0
Source DB: PubMed Journal: J Hematol Oncol ISSN: 1756-8722 Impact factor: 17.388
Fig. 1The functions of exosomes within TME in facilitating the development and progression of HCC. Exosome-mediated immune regulation is involved in modulation of the TME with immunosuppressive and tolerogenic characteristics. Multiple processes are involved in HCC, including tumor survival, growth, angiogenesis, invasion, and metastasis. The specific mechanisms involved in molding the TME for HCC include energy metabolism regulation, stimulatory signal supply, and inhibitory signal circumvention. In addition, exosomes induce angiogenesis by changing the biological characteristics of endothelial cells and directly regulating proangiogenic and propermeability factors. Additionally, exosomes may lead to HCC metastatic invasion by EMT, ECM degradation, and vascular leakage. Finally, the association between exosomes and drug resistance suggests the involvement of complex mechanisms of chemoresistance in the TME
The roles of exosomes within TME in HCC development and progression
| Exosomal cargos | Regulation | Biological function | Mechanism | Reference |
|---|---|---|---|---|
| 14-3-3ζ | Increased | Impair antitumor function | Inhibit the antitumor functions of TILs and the vitality and proliferation of peripheral blood CD3+ T cells | [ |
| MICA*008 | Increased | Impair cytotoxic function | Induce NKG2D downregulation on NK cell surface | [ |
| HCC antigens | Increased | Promote immune responses | Activate immune response mediated by DCs | [ |
| Not mentioned | Unvaried | Regulate immunosuppression | Alter the immunosuppressive status through STAT3 pathway in macrophages | [ |
| miR-490 | Increased | Inhibit metastasis | Mast cells are stimulated by HCV-E2 and secrete exosomes to inhibit the ERK1/2 pathway | [ |
| miR-142, miR-223 | Increased | Inhibit proliferation | Decrease reporter protein expression and endogenously express stathmin-1 and insulin-like growth factor-1 receptor | [ |
| linc-RoR | Increased | Regulate energy metabolism | Activate microRNA-145/HIF-1α/PDK1 pathway and enhance the glycolysis process | [ |
| Induce chemoresistance | Activate TGF-β signaling and promote colony formation of CD133+ T-IC | [ | ||
| miRNA | Increased | Promote migration and invasion | Induce TGF-β and TAK1 expression | [ |
| miR-155 | Increased | Promote formation and development | Promote inflammation and positively correlate with IL-6 or IL-8 levels | [ |
| miR-1247-3p | Increased | Promote metastasis | Target B4GALT3 and activate β1-integrin–NF-κB pathway | [ |
| miR-30a | Decreased | Promote proliferation and metastasis | Mediate Beclin 1 and Atg5-dependent autophagy | [ |
| miR-320a | Decreased | Promote metastasis | Target PBX3 and MAPK pathway, induce EMT, and upregulate CDK2 and MMP-2 expression | [ |
| miR-122 | Decreased | Promote proliferation | IGF1 prevents intercellular exosomal transfer of miR-122 | [ |
| Increase | Induce chemosensitivity | Induce chemosensitivity (5-FU and sorafenib) | [ | |
| miR-9-3p | Decreased | Promote proliferation | Regulate HBGF-5 and ERK1/2 expression | [ |
| VASN | Increased | Promote HUVECs cells migration | Not mentioned | [ |
| RNAs, miRNAs | Polytropic | Associated with the degree of lumen formation | Not mentioned | [ |
| miR-210-3p | Increased | Increase angiogenesis | Inhibit the expression of SMAD4 and STAT6 in ECs | [ |
| lincRNA H19 | Increased | Increase angiogenesis | Increase VEGF release and the production of VEGF-R1 | [ |
| miR-221 | Increased | Increase angiogenesis | Activate SAND/NF-κB pathway and upregulate CXCL16 expression | [ |
| miR-21 | Increased | Increase angiogenesis | Activate the STAT3/VEGF pathway | [ |
| Not mentioned | Not mentioned | Induce chemoresistance | Activate HGF/c-Met/Akt pathways and restrain apoptosis | [ |
| Fibronectin1 COL2A1, FGG | Increased | Promote metastasis | Induce either partial or total EMT | [ |
| RNAs, proteins | Polytropic | Promote migration and invasion | Activate PI3K/AKT and MAPK pathways in MIHA and increase MMP-2 and MMP-9 secretion | [ |
| miR-103 | Increased | Promote metastasis | Inhibit the expression of VE-Cad, p120, and ZO-1 | [ |
| AFP | Increased | Promote immune responses; Inhibit proliferation | Enhance CD8+ T lymphocytes response, improve IFN-γ and IL-2 expression | [ |
| HSP | Increased | Promote immune responses | Improve tumor immunogenicity and induce NK cell responses | [ |
| PD-L1 | Increased | Promote proliferation | Suppress T cell activation in the draining lymph node | [ |
| miR-26a | Increased | Inhibit proliferation | Bind to HepG2 cells via the scavenger receptor class B type 1-Apo-A1 complex | [ |
| Doxorubicin | Increased | Inhibit proliferation | imDCs were engineered to express Lamp2b fused with v integrin-specific iRGD peptide | [ |
| lincRNA-VLDLR | Increased | Induce chemoresistance | Increase ABCG2 expression and restrain apoptosis | [ |